United States - English - NLM (National Library of Medicine)

stratus pharmaceuticals inc - castor oil (unii: d5340y2i9g) (castor oil - unii:d5340y2i9g) - castor oil 788 mg in 1 g - venelex™ ointment is a wound dressing for topical use in the management of chronic and acute wounds, and dermal ulcers including: pressure ulcers (stage i-iv), venous stasis ulcers, diabetic ulcers, first and second degree burns, surgical wounds, traumatic wounds, superficial wounds, ulcers resulting from arterial insufficiency and grafted wound/donor sites. venelex™ ointment is contraindicated in persons who have shown hypersensitivity to balsam peru, petrolatum or any of the other ingredients used in this ointment. venelex™ ointment is easy to apply and quickly reduces odors frequently accompanying a decubitus ulcer. the wound may be left open or appropriate dressing applied. please note that wounds generally heal poorly in the presence of hemoglobin or zinc deficiency.

India - English - Central Drugs Standard Control Organization

axyzen life - lycopene - syr - with antioxidant - 200ml

India - English - Central Drugs Standard Control Organization

axyzen life - lycopene - cap - 2000mcg( with antioxidants) - 10*1*10

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 200 mg - celecoxib capsules are indicated for the management of the signs and symptoms of oa [see clinical studies (14.1)] . for the management of the signs and symptoms of ra [see clinical studies (14.2)] . for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3)] . for the management of the signs and symptoms of as [see clinical studies (14.4)] . for the management of acute pain in adults [see clinical studies (14.5)] . for the management of primary dysmenorrhea [see clinical studies (14.5)] . celecoxib capsules are contraindicated in the following patients: pregnancy category c. pregnancy category d from 30 weeks of gestation onward. use of nsaids, including celecoxib capsules, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including celecoxib capsules, in pregnant women starting at 30 weeks of gestation. there are no adequate and well-controlled studies of celecoxib capsules i

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 27.602 mg/ml equivalent to cephalexin 25 mg/ml (+5% stability overage);   - granules for oral suspension - 125 mg/5ml - active: cefalexin monohydrate 27.602 mg/ml equivalent to cephalexin 25 mg/ml (+5% stability overage)   excipient: apple flavour 648601 citric acid guar gum iron oxide yellow raspberry flavour 501183 tp0551 saccharin sodium simeticone sodium benzoate strawberry flavour 052303 bp0551 sucrose tutti frutti flavour 051880 ap0551 - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: · bacterial sinusitis caused by streptococci, streptococcus pneumoniae, and staphylococcus aureus (methicillin -sensitive only); ·respiratory tract infections caused by s. pneumoniae and streptococcus pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); · otitis media due to s. pneumoniae, haemophilus influenzae, staphylococci, streptococci, and moraxella catarrhalis; · skin and skin-structure infections caused by staphylococci and/or streptococci; · bone infections caused by staphylococci and/or proteus mirabilis; · genitourinary tract infections, including acute prostatitis, caused by eschericia coli, p. mirabilis, and klebsiella pneumoniae; · dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 55.206 mg/ml equivalent to cephalexin 50 mg/ml (+5% stability overage);   - granules for oral suspension - 250 mg/5ml - active: cefalexin monohydrate 55.206 mg/ml equivalent to cephalexin 50 mg/ml (+5% stability overage)   excipient: apple flavour 648601 citric acid guar gum iron oxide yellow raspberry flavour 501183 tp0551 saccharin sodium simeticone sodium benzoate strawberry flavour 052303 bp0551 sucrose tutti frutti flavour 051880 ap0551 - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: · bacterial sinusitis caused by streptococci, streptococcus pneumoniae, and staphylococcus aureus (methicillin -sensitive only); ·respiratory tract infections caused by s. pneumoniae and streptococcus pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); · otitis media due to s. pneumoniae, haemophilus influenzae, staphylococci, streptococci, and moraxella catarrhalis; · skin and skin-structure infections caused by staphylococci and/or streptococci; · bone infections caused by staphylococci and/or proteus mirabilis; · genitourinary tract infections, including acute prostatitis, caused by eschericia coli, p. mirabilis, and klebsiella pneumoniae; · dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 100 mg - carefully consider the potential benefits and risks of celebrex and other treatment options before deciding to use celebrex. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see warnings and precautions (5) ] celebrex is indicated for relief of the signs and symptoms of oa [see clinical studies (14.1) ] celebrex is indicated for relief of the signs and symptoms of ra [see clinical studies (14.2) ] celebrex is indicated for relief of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3) ] celebrex is indicated for the relief of signs and symptoms of as [see clinical studies (14.4) ] celebrex is indicated for the management of ap in adults [see clinical studies (14.5) ] celebrex is indicated for the treatment of pd [see clinical studies (14.5) ] celebrex is contraindicated: - in patients with known hypersensitivity to celecoxib, aspirin, or other nsaids. - in patients who have demonstrated allergic-type reactions to su

United States - English - NLM (National Library of Medicine)

strategic pharmaceutical solutions, inc. dba vetsource - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis skin and skin structure infections caused by staphylococci and/or streptococci bone infections caused by staphylococci and/or p. mirabilis genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and k. pneumoniae note - culture and susceptibility tests should be initiated prior to and during

United States - English - NLM (National Library of Medicine)

a-s medication solutions - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 200 mg - celecoxib capsules are indicated for the management of the signs and symptoms of oa [see clinical studies (14.1) ] for the management of the signs and symptoms of ra [see clinical studies (14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3) ] for the management of the signs and symptoms of as [see clinical studies (14.4) ] for the management of acute pain in adults [see clinical studies (14.5) ] for the management of primary dysmenorrhea [see clinical studies (14.5) ] celecoxib capsules are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see warnings and precautions (5.7, 5.9) ]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids, have been reported in such patients [see warnings and precautions (5.7, 5.8) ].

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib 200 mg - carefully consider the potential benefits and risks of celebrex and other treatment options before deciding to use celebrex. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see warnings and precautions (5) ] celebrex is indicated for relief of the signs and symptoms of oa [see clinical studies (14.1) ] celebrex is indicated for relief of the signs and symptoms of ra [see clinical studies (14.2) ] celebrex is indicated for relief of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3) ] celebrex is indicated for the relief of signs and symptoms of as [see clinical studies (14.4) ] celebrex is indicated for the management of ap in adults [see clinical studies (14.5) ] celebrex is indicated for the treatment of pd [see clinical studies (14.5) ] celebrex is contraindicated: - in patients with known hypersensitivity to celecoxib, aspirin, or other nsaids. - in patients who have demonstrated allergic-type reactions to su